Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. EYBELIS OPHTHALMIC SOLUTION 0.002% [SIN16150P]

EYBELIS OPHTHALMIC SOLUTION 0.002% [SIN16150P]

Active ingredients: EYBELIS OPHTHALMIC SOLUTION 0.002%

Last updated 26 October 2025

Product Info

EYBELIS OPHTHALMIC SOLUTION 0.002%

[SIN16150P]

Product information

Active Ingredient and Strength

OMIDENEPAG ISOPROPYL - 0.02 MG/ML

Dosage Form

SOLUTION, STERILE

Manufacturer and Country

SANTEN PHARMACEUTICAL CO., LTD. SHIGA PLANT - JAPAN

Registration Number

SIN16150P

Licence Holder

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01EX06

Therapeutic indications
Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Posology and method of administration
Posology
The recommended dose is one drop in the affected eye(s) once daily in the evening.

If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.

Paediatric population

The safety and efficacy of omidenepag isopropyl in children and adolescents have not yet been established. No data are available.

Method of administration
For ocular use.

Be careful not to touch the tip of the bottle to the eye directly in order to avoid the contamination of the drug.

If more than one topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.

Benzalkonium chloride may change the colour of the contact lenses. Contact lens wearers should remove the contact lenses before using this product and put them back after 5–10 minutes.

Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in ‘Description’ – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Patients with aphakic eyes or intraocular lens (IOL) inserted eyes (see ‘Undesirable effects’ – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Concomitant use with tafluprost (see ‘Interactions’ – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).